Stocks and Investing
Stocks and Investing
Wed, September 13, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, September 12, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Renza Maintained (ADCT) at Buy with Decreased Target to $8 on, Sep 12th, 2023
Gregory Renza of RBC Capital, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $9 to $8 on, Sep 12th, 2023.
Gregory has made no other calls on ADCT in the last 4 months.
There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 2 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Cheng of "JP Morgan" Upgraded from Sell to Hold on, Thursday, August 10th, 2023
- Jeffrey Hung of "Morgan Stanley" Reiterated at Hold and Held Target at $5 on, Tuesday, July 11th, 2023
This is the rating of the analyst that currently disagrees with Gregory
- Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $12 on, Tuesday, July 25th, 2023
Contributing Sources